ChemicalBook > Product Catalog >API >Blood System Drugs >Anticoagulant and Antiplatelet Drugs >TICAGRELOR

TICAGRELOR

TICAGRELOR Suppliers list
Company Name: Beijing Cooperate Pharmaceutical Co.,Ltd.
Tel: +86-10-60279497 +86(0)15646567669
Email: sales01@cooperate-pharm.com
Products Intro: Product Name:TICAGRELOR
CAS:274693-27-5
Purity:98% Package:100G;1KG;5KG;10KG;25KG;50KG;100KG
Company Name: Chengdu Henghui Pharm Tec Co. Ltd.
Tel: 13540674322 15828370308,QQ:2879822141
Email: service@2hpharm.com
Products Intro: Product Name:TICAGRELOR
CAS:274693-27-5
Company Name: Nanjing Gold Pharmaceutical Technology Co. Ltd.
Tel: 025-84209270 15906146951
Email: wgp@nanjing-pharmaceutical.com
Products Intro: Product Name:TICAGRELOR
CAS:274693-27-5
Purity:99% Package:50KG;25KG;10KG;5KG;1KG
Company Name: Arromax Pharmatech Co., Ltd.  Gold
Tel:0512-62959601 ,15995748448 ;QQ2063939626
Email:meizhang.sales@arromax.com
Products Intro:Product Name:Ticagrelor
CAS:274693-27-5
Purity:>99.5% 单杂0.1%以下 提供各种稳定晶型 Package:100g,500g,1kg及以上 Remarks:API
Company Name: Shanghai Pansopharm Technology Co., Ltd.  Gold
Tel:+86 (21) 2096-2833 / +86 15618308650
Email:sales@pansopharm.com
Products Intro:Product Name:Ticagrelor
CAS:274693-27-5
Purity:99% HPLC Package:1G;1KG
TICAGRELOR Basic information
Indications and Usage Mechanisms of Action Clinical Research
Product Name:TICAGRELOR
Synonyms:TICAGRELOR;(1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol;Azd 6140;Unii-glh0314rvc;(1S,2S,3R,5S)-3-(7-(((1S,2S)-2-(3,4-difluorophenyl)cyclopropyl)aMino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyriMidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol;AR-C 126532XX;Ticagrelor(AR-C 126532XX;Ticagrelor (AZD6140)
CAS:274693-27-5
MF:C23H28F2N6O4S
MW:522.574
EINECS:
Product Categories:Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds;Ticagrelor;AZD6140;Cardiovascular APIs
Mol File:274693-27-5.mol
TICAGRELOR Structure
TICAGRELOR Chemical Properties
density 1.67
Safety Information
MSDS Information
TICAGRELOR Usage And Synthesis
Indications and UsageTicagrelor, a new platelet aggregation inhibitor successfully developed by AstraZeneca (U.S.), is the world’s first reversible combination orally-administered P2Y12 adenosine diphosphate receptor antagonist.
It is used to reduce cardiovascular death and heart attacks in patients with acute coronary syndrome (ACS.) Rapid onset after oral administration, and can effectively improve symptoms of patients with ACS. Thienopyridines is a reversible P2Y12 inhibitor, so it is particularly applicable towards patients who need to undergo anticoagulant therapy before surgery.
Mechanisms of ActionReversibly acts on the 2 purine receptor (purinoceptor 2, P2,) subtype P2Y12, of vascular smooth muscle cells (VSMC,) does not require metabolic activation, and has a significant inhibitory effect on platelet aggregation induced by adenosine diphosphate (ADP.)
Clinical ResearchTicagrelor was approved by the U.S. Food and Drug Administration (FDA) on the basis of PLATO clinical studies. PLATO was a 43 country, 862 center randomized, double-blind, multi-centered study which included 18,624 patients hospitalized for ACS. Patients were randomly given either aspirin plus ticagrelor, or aspirin plus clopidogrel, two antiplatelet regimens. The study showed a 16% reduction in risk of heart attack, stroke, or death in the group taking Ticagrelor compared to those who took clopidogrel. The PLATO study demonstrated the benefits of Ticagrelor for patient survival, and is currently widely recommended as a treatment strategy for ACS. In addition, at the same time it reduces operative myocardial infarction and thrombosis after stent implantation, it also does not increase the overall risk of fatal bleeding and other serious adverse effects.
Ticagrelor however has two shortcomings. First, it must be taken twice a day, compared to once a day for clopidogrel, and secondly, it may cause adverse effects such as breathing difficulties, significantly more than with the latter. Its half-life is only 12 hours, and taken twice a day, a challenge for patients with poor compliance. In practice, it has also been found that around 20% of patients treated with clopidogrel do not follow their prescriptions, and these patients are even less likely to take the prescribed doses when using ticagrelor. Thus, as a rapidly reversible drug, direct withdrawal will likely increase the risk of acute thrombosis, causing myocardial infection or stroke.
Chemical PropertiesWhite Solid
UsesTicagrelor, the first reversible oral P2Y12 receptor antagonist, provides faster, greater, and more consistent ADP-receptor inhibition than Clopidogrel. Used in the treatment of acute coronary syndromes (ACS)
UsesTicagrelor is the first reversibly binding oral P2Y12 receptor antagonist, also inhibits CYP2C9 and 4-hydroxylation with IC50 of 10.5 μM and 8.2 μM respectively
DefinitionChEBI: A triazolopyrimidine that is an adenosine isostere; the cyclopentane ring is similar to ribose and the nitrogen-rich [1,2,3]triazolo[4,5-d]pyrimidine moiety resembles the nucleobase adenine. A platelet aggregation inhibitor which is used for p evention of thromboembolic events in patients with acute coronary syndrome.
TICAGRELOR Preparation Products And Raw materials
Tag:TICAGRELOR(274693-27-5) Related Product Information
Everolimus Y27632 (hydrochloride) Selumetinib MK-2206 2HCl ABT 263 N-(3-(5-(4-Chlorophenyl)-1H-pyrrolo[2,3-B]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonaMide Prasugrel Clopidogrel TICAGRELOR tranylcypromine